Evidence map›Paper›PMID 38528318›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024

Plasma glial fibrillary acidic protein in the visual and language variants of Alzheimer's disease.

Irene Sintini, Neha Atulkumar Singh, Danni Li, Michelle M Mielke, Mary M Machulda, Christopher G Schwarz, Matthew L Senjem, Clifford R Jack, Val J Lowe, Jonathan Graff-Radford and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Plasma glial fibrillary acidic protein in the visual and language variants of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Irene SintiniDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Neha Atulkumar SinghDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Danni LiDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA.
Michelle M MielkeDepartment of Epidemiology and Prevention, Wake Forest University, Winston-Salem, North Carolina, USA.
Mary M MachuldaDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.
Christopher G SchwarzDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Matthew L SenjemDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Val J LoweDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Keith A JosephsDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Jennifer L WhitwellDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Mayo Clinic · USUniversity of Minnesota · USWake Forest University · US

Funding

Molecular and structural imaging in atypical Alzheimer's disease: a longitudinal studyR01AG050603 · NIA · MAYO CLINIC ROCHESTER · PI WHITWELL, JENNIFER LOUISE · 2016 to 2025
$5.9M
NIA NIH HHS R01 AG050603NIH HHS R01-AG50603
6 · The paper itself

Abstract

introductionGlial fibrillary acidic protein (GFAP) in plasma is a proxy for astrocytic activity and is elevated in amyloid-β (Aβ)-positive individuals, making GFAP a potential blood-based biomarker for Alzheimer's disease (AD).

methodsWe assessed plasma GFAP in 72 Aβ-positive participants diagnosed with the visual or language variant of AD who underwent Aβ- and tau-PET. Fifty-nine participants had follow-up imaging. Linear regression was applied on GFAP and imaging quantities.

resultsGFAP did not correlate with Aβ- or tau-PET cross-sectionally. There was a limited positive correlation between GFAP and rates of tau accumulation, particularly in the language variant of AD, although associations were weaker after removing one outlier patient with the highest GFAP level. DISCUSSION: Among Aβ-positive AD participants with atypical presentations, plasma GFAP did not correlate with levels of AD pathology on PET, suggesting that the associations between GFAP and AD pathology might plateau during the advanced phase of the disease.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBiomarkersGlial Fibrillary Acidic ProteinPositron-Emission Tomographytau ProteinsAgedAged, 80 and overBrainCross-Sectional StudiesFemaleHumansLanguageMaleAmyloid beta-PeptidesBiomarkersGlial Fibrillary Acidic Proteintau Proteinsamyloid‐betaatypical Alzheimer's diseaseGFAPtau

Identifiers

PMID38528318
PMCPMC11095421
OpenAlexW4393199097

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.